Longaeva Partners’s Summit Therapeutics SMMT Stock Holding History

Longaeva Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-57,282	Closed	-$1.09M	–	400
2026 Q1	$1.09M	Buy	+57,282	New	+$926K	0.04%	171

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Longaeva Partners's SMMT Position: Q2 2026 in Review

Longaeva Partners sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 57,282 shares — an estimated $1.09M sold.

Longaeva Partners first reported a position in SMMT in Q1 2026 and held it in 1 quarter. The position peaked at $1.09M in Q1 2026. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Longaeva Partners reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
Longaeva Partners sold 57,282 Summit Therapeutics shares in Q2 2026, an estimated $1.09M.
Longaeva Partners first reported a position in Summit Therapeutics in Q1 2026 and held it in 1 quarter.
Longaeva Partners's Summit Therapeutics position peaked at $1.09M in Q1 2026.
242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.